Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Bile Acids and Biliary Fibrosis

Cells(2023)10.3390/cells12050792Source: DataRank Database

Bile Acids and Biliary Fibrosis is a research paper published in Cells (2023). On theSindex it has a DataRank of 0. It has been cited 22 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access22 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 3.34)OA: goldTopics (22)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Phillip B. Hylemon ORCID,Huiping Zhou ORCID,Sayed Obaidullah Aseem ORCID

Live enrichment

PubMed:36899928 OpenAlex:https://openalex.org/W4323043725

VA Research Career Scientist

Grant: IK6BX004477

VA Research Career Scientist

Grant: I01BX004033

VA Research Career Scientist

Grant: 1IS1BX005517-01

VA Research Career Scientist

Grant: 1IS1BX004777-01

VA Research Career Scientist

Grant: R01 DK104893

VA Research Career Scientist

Grant: R01DK-057543

VA Research Career Scientist

Grant: R21 AA026629-01

FWCI

3.34

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2073-4409/12/5/792/pdf?version=1677761033

publisherhttps://www.mdpi.com/2073-4409/12/5/792/pdf?version=1677761033

publisherhttps://www.mdpi.com/2073-4409/12/5/792/pdf

journalhttps://doi.org/10.3390/cells12050792

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36899928

Fields of Study

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and TreatmentsCholangiocarcinoma and Gallbladder Cancer Studies

MeSH Terms

AnimalsBile Acids and SaltsCholestasisDisease Models, AnimalFibrosisHumansLiver Diseases

Keywords

CholestasisPrimary sclerosing cholangitisFibrosisMedicineBile acidPathogenesisObeticholic acidUrsodeoxycholic acidGastroenterologyInternal medicineReceptorDisease

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (10)

Obeticholic Acid: First Global Approval

Drugs(2016)

OpenAlex related

10.1007/s40265-016-0616-x

Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis

Journal of Experimental Pharmacology(2020)

OpenAlex related

10.2147/jep.s267375

Fibrates for Primary Biliary Cholangitis: What’s All the Hype?

Annals of Hepatology(2017)

OpenAlex related

10.5604/01.3001.0010.2709

Risk stratification and treatment of primary biliary cholangitis

Revista Española de Enfermedades Digestivas(2018)

OpenAlex related

10.17235/reed.2018.5662/2018

Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy

Digestive and Liver Disease(2019)

OpenAlex related

10.1016/j.dld.2018.11.069

FRI-067-Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database

Journal of Hepatology(2019)

OpenAlex related

10.1016/s0618-8278(19)30817-5

In Silico Prediction and Pharmacokinetic Comparison of Ursodeoxycholic Acid and Obeticholic Acid in the Management of Primary Biliary Cholangitis

Journal of Drug Delivery and Therapeutics(2021)

OpenAlex related

10.22270/jddt.v11i2-s.4669

Faculty Opinions recommendation of Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature(2016)

OpenAlex related

10.3410/f.725276401.793518928

Bile acid derivatives for people with primary sclerosing cholangitis

Cochrane Database of Systematic Reviews(2016)

OpenAlex related

10.1002/14651858.cd012061

Efficacy and tolerance of obeticholic acid in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid in real life: interim analysis of the OCARELIFE study

Journal of Hepatology(2020)

OpenAlex related

10.1016/s0168-8278(20)31458-6